Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy

Basit Öğe Kaydı
dc.contributor.authorNalcaci, Serhad
dc.contributor.authorAkkin, Cezmi
dc.contributor.authorAfrashi, Filiz
dc.date.accessioned2019-10-27T09:45:02Z
dc.date.available2019-10-27T09:45:02Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: To investigate the efficacy of single dose intravitreal dexamethasone implant in patients with diabetic macular edema (DME) resistant to anti-VEGF therapy. Materials and Methods: Twenty eyes of 14 patients (8 male, 6 female; mean age, 65 +/- 5.7 years) with DME resistant to intravitreal ranibizumab injections were studied. A single intravitreal dexamethasone implant was injected into each eye and patients were followed up for 6 months. Response to therapy was assessed monthly by measuring intraocular pressure (IOP), best-corrected visual acuity (BCVA), and central foveal thickness (CFT). Results: Baseline (before injection) IOP was 14.9 +/- 2.7 mmHg and did not change significantly in the six months following injection. Baseline BCVA was 1.04 +/- 0.35 LogMAR and improved to 0.86 +/- 0.31 at month 1 without statistical significance (p=0.056). CFT was significantly lower in all monthly measurements compared to its baseline value of 682.21,229.2 mu m. During the follow-up period, endophthalmitis, significant cataract, or rhegmatogenous retinal detachment were not detected. Conclusion: Intravitreal dexamethasone implant injection is associated with significant CFT reduction for up to six months without causing any complications. Although BCVA did not improve in parallel with the CFT reduction, intravitreal dexamethasone implant should be considered as an effective and safe treatment option in the management of DME patients resistant to anti-VEGF injections.en_US
dc.identifier.doi10.4274/tjo.galenos.2018.84665en_US
dc.identifier.endpage77en_US
dc.identifier.issn1300-0659
dc.identifier.issn2147-2661
dc.identifier.issue2en_US
dc.identifier.pmid31055891en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://doi.org/10.4274/tjo.galenos.2018.84665
dc.identifier.urihttps://hdl.handle.net/11454/29084
dc.identifier.volume49en_US
dc.identifier.wosWOS:000466509800006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Ophthalmological Socen_US
dc.relation.ispartofTurk Oftalmoloji Dergisi-Turkish Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDexamethasoneen_US
dc.subjectdiabetic macular edemaen_US
dc.subjectranibizumaben_US
dc.subjectvascular endothelial growth factoren_US
dc.titleDexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu